Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of subclonal resistance mutations on targeted cancer therapy.

Nature reviews. Clinical oncology - 1 Jun 2016

Schmitt Michael W, Loeb Lawrence A, Salk Jesse J

Abstract excerpt

Clinical oncology is being revolutionized by the increasing use of molecularly targeted therapies. This paradigm holds great promise for improving cancer treatment; however, allocating specific therapies to the patients who are most likely to derive a durable benefit continues to represent a considerable challenge. Evidence continues to emerge that cancers are characterized by extensive intratumour genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Genes, erbB-1
Share to MAP Kinase Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Molecular Targeted Therapy

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-kit

Source

Open in PubMed Open full text

Identifiers

PMID: 26483300
DOI: 10.1038/nrclinonc.2015.175
PMCID: PMC4838548

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of subclonal resistance mutations on targeted cancer therapy.PMID 26483300Read ↗

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.Semantic proximity Read ↗

Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.Semantic proximity Read ↗

The emergence of resistance to targeted cancer therapeutics.Semantic proximity Read ↗

Tumour heterogeneity and the evolution of polyclonal drug resistance.Semantic proximity Read ↗

Somatic alterations as the basis for resistance to targeted therapies.Semantic proximity Read ↗

Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapySemantic proximity Read ↗

The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicineSemantic proximity Read ↗

Mechanisms and insights into drug resistance in cancerSemantic proximity Read ↗

Targeting molecular subtypes in solid cancers: successes and failures.Semantic proximity Read ↗

Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer BiologySemantic proximity Read ↗

Circumventing Cancer Drug Resistance in the Era of Personalized MedicineSemantic proximity Read ↗

Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.